Stroke treatment academic industry roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies

Gregory W. Albers, Larry B. Goldstein, David C Hess, Lawrence R. Wechsler, Karen L. Furie, Philip B. Gorelick, Patty Hurn, David S. Liebeskind, Raul G. Nogueira, Jeffrey L. Saver

Research output: Contribution to journalReview article

125 Citations (Scopus)

Abstract

Background and Purpose-The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of acute and restorative stroke therapies. Summary of Review-At the STAIR VII recommendations for strategies to maximize the use of intravenous thrombolytics through targeting public education, and the refinement of current treatment exclusion criteria were proposed. Increased utilization of mechanical devices for intra-arterial recanalization can be achieved by obtaining more definitive evidence of efficacy in randomized clinical trials, identification of patient characteristics associated with treatment efficacy, optimization of technical approaches, clarification of effective time windows, and development of approaches to limit complications. Neuroprotective strategies remain viable; recommendations for further study of these agents include an emphasis on rapid administration, consideration of the systemic effects of ischemic stroke, prevention of complications associated with early reperfusion, a focus on agents with multiple mechanisms of action, and consideration of possible interactions between neuroprotective and thrombolytic therapies. Conclusions-Extending intravenous thrombolysis to a broader patient population, clarifying the risk and benefits of intra-arterial reperfusion therapies, and further development of neuroprotective therapies were the key recommendations from STAIR VII.

Original languageEnglish (US)
Pages (from-to)2645-2650
Number of pages6
JournalStroke
Volume42
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Industry
Stroke
Therapeutics
Reperfusion
Thrombolytic Therapy
Randomized Controlled Trials
Education
Equipment and Supplies
Population

Keywords

  • acute stroke
  • basic science
  • drug trials
  • neuroprotection
  • thrombolysis

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Stroke treatment academic industry roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. / Albers, Gregory W.; Goldstein, Larry B.; Hess, David C; Wechsler, Lawrence R.; Furie, Karen L.; Gorelick, Philip B.; Hurn, Patty; Liebeskind, David S.; Nogueira, Raul G.; Saver, Jeffrey L.

In: Stroke, Vol. 42, No. 9, 01.09.2011, p. 2645-2650.

Research output: Contribution to journalReview article

Albers, Gregory W. ; Goldstein, Larry B. ; Hess, David C ; Wechsler, Lawrence R. ; Furie, Karen L. ; Gorelick, Philip B. ; Hurn, Patty ; Liebeskind, David S. ; Nogueira, Raul G. ; Saver, Jeffrey L. / Stroke treatment academic industry roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. In: Stroke. 2011 ; Vol. 42, No. 9. pp. 2645-2650.
@article{93a3f03aff0e4fafa4726ed56934ba20,
title = "Stroke treatment academic industry roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies",
abstract = "Background and Purpose-The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of acute and restorative stroke therapies. Summary of Review-At the STAIR VII recommendations for strategies to maximize the use of intravenous thrombolytics through targeting public education, and the refinement of current treatment exclusion criteria were proposed. Increased utilization of mechanical devices for intra-arterial recanalization can be achieved by obtaining more definitive evidence of efficacy in randomized clinical trials, identification of patient characteristics associated with treatment efficacy, optimization of technical approaches, clarification of effective time windows, and development of approaches to limit complications. Neuroprotective strategies remain viable; recommendations for further study of these agents include an emphasis on rapid administration, consideration of the systemic effects of ischemic stroke, prevention of complications associated with early reperfusion, a focus on agents with multiple mechanisms of action, and consideration of possible interactions between neuroprotective and thrombolytic therapies. Conclusions-Extending intravenous thrombolysis to a broader patient population, clarifying the risk and benefits of intra-arterial reperfusion therapies, and further development of neuroprotective therapies were the key recommendations from STAIR VII.",
keywords = "acute stroke, basic science, drug trials, neuroprotection, thrombolysis",
author = "Albers, {Gregory W.} and Goldstein, {Larry B.} and Hess, {David C} and Wechsler, {Lawrence R.} and Furie, {Karen L.} and Gorelick, {Philip B.} and Patty Hurn and Liebeskind, {David S.} and Nogueira, {Raul G.} and Saver, {Jeffrey L.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1161/STROKEAHA.111.618850",
language = "English (US)",
volume = "42",
pages = "2645--2650",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Stroke treatment academic industry roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies

AU - Albers, Gregory W.

AU - Goldstein, Larry B.

AU - Hess, David C

AU - Wechsler, Lawrence R.

AU - Furie, Karen L.

AU - Gorelick, Philip B.

AU - Hurn, Patty

AU - Liebeskind, David S.

AU - Nogueira, Raul G.

AU - Saver, Jeffrey L.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background and Purpose-The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of acute and restorative stroke therapies. Summary of Review-At the STAIR VII recommendations for strategies to maximize the use of intravenous thrombolytics through targeting public education, and the refinement of current treatment exclusion criteria were proposed. Increased utilization of mechanical devices for intra-arterial recanalization can be achieved by obtaining more definitive evidence of efficacy in randomized clinical trials, identification of patient characteristics associated with treatment efficacy, optimization of technical approaches, clarification of effective time windows, and development of approaches to limit complications. Neuroprotective strategies remain viable; recommendations for further study of these agents include an emphasis on rapid administration, consideration of the systemic effects of ischemic stroke, prevention of complications associated with early reperfusion, a focus on agents with multiple mechanisms of action, and consideration of possible interactions between neuroprotective and thrombolytic therapies. Conclusions-Extending intravenous thrombolysis to a broader patient population, clarifying the risk and benefits of intra-arterial reperfusion therapies, and further development of neuroprotective therapies were the key recommendations from STAIR VII.

AB - Background and Purpose-The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of acute and restorative stroke therapies. Summary of Review-At the STAIR VII recommendations for strategies to maximize the use of intravenous thrombolytics through targeting public education, and the refinement of current treatment exclusion criteria were proposed. Increased utilization of mechanical devices for intra-arterial recanalization can be achieved by obtaining more definitive evidence of efficacy in randomized clinical trials, identification of patient characteristics associated with treatment efficacy, optimization of technical approaches, clarification of effective time windows, and development of approaches to limit complications. Neuroprotective strategies remain viable; recommendations for further study of these agents include an emphasis on rapid administration, consideration of the systemic effects of ischemic stroke, prevention of complications associated with early reperfusion, a focus on agents with multiple mechanisms of action, and consideration of possible interactions between neuroprotective and thrombolytic therapies. Conclusions-Extending intravenous thrombolysis to a broader patient population, clarifying the risk and benefits of intra-arterial reperfusion therapies, and further development of neuroprotective therapies were the key recommendations from STAIR VII.

KW - acute stroke

KW - basic science

KW - drug trials

KW - neuroprotection

KW - thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=80052404082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052404082&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.111.618850

DO - 10.1161/STROKEAHA.111.618850

M3 - Review article

VL - 42

SP - 2645

EP - 2650

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 9

ER -